Savara, Inc. Aktie News

NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Savara Inc. (NASDAQ: SVRA).

LOS ANGELES , Nov. 4, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Savara Inc. ("Savara" or the "Company") (NASDAQ: SVRA) have opportunity to lead the securities fraud class action lawsuit.

LOS ANGELES, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The DJS Law Group reminds investors of a class action lawsuit against Savara Inc. (“Savara” or “the Company”) (NASDAQ: SVRA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of SVRA during the class perio...

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management team will host 1x1 meetings and participate in fireside chats at two upcoming healthcare conferences. Fireside Chats: Guggenheim 2nd Annual Healthcare Innovation Conference November 10, 2025, 8:30 ...

LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming November 7, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA) securities between March 7, 2024 and May 23, 2025, inclusive (the “Class Period”).

LOS ANGELES , Nov. 3, 2025 /PRNewswire/ -- The DJS Law Group  reminds investors of a class action lawsuit against Savara Inc. ("Savara " or "the Company") (NASDAQ: SVRA ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of SVRA during the class period...

NEW YORK , Nov. 2, 2025 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Savara Inc. (NASDAQ: SVRA) between March 7, 2024 and May 23, 2025, both dates inclusive (the "Class Period"), of the important November 7, 2025 lead plaintiff deadline. So what: If you purchased Savara securities during the Class Period you may be entitled to comp...

LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the closing of its previously announced underwritten public offering of 28,452,381 shares of common stock, including 4,642,857 shares of common stock sold pursuant to the exercise in full by the underwriters of their option to purchase add...